{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"CS1 (CD2 subset-1, also known as CRACC, SLAMF7, CD319) expression levels in multiple myeloma cells were analyzed from bone-marrow aspirates collected at baseline and at time of progression through mean fluorescent intensity.\n\nThe following conditions were considered to describe multiple myeloma cells expressing CS1 (CS1+/CD38++/CD138+/CD56+/CD19-/CD45DIM)","groups":[{"description":"Participants receiving a combination of Elotuzumab (E) Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG000","title":"E-Ld Cohort"},{"description":"Participants receiving a combination of Lenalidomide (L) Dexamethasone (d) in a 28 day cycle","id":"OG001","title":"Ld Cohort"}],"populationDescription":"All treated participants with measurements available at baseline and at time of progression.\n\nNo participants in any of the 2 cohorts had available measurements both at baseline and time of progression","reportingStatus":"POSTED","timeFrame":"From baseline (screening) to time of progression (up to approximately 54 months)","title":"Change From Baseline to Progression of the Cell Surface Expression of CS1 From Bone Marrow-Derived Multiple Myeloma (MM) Cells","type":"PRIMARY"}